Table 1 Baseline characteristics of the NDMM patients.

From: 11C-acetate positron emission tomography is more precise than 18F-fluorodeoxyglucose positron emission tomography in evaluating tumor burden and predicting disease risk of multiple myeloma

Characteristics

n = 64

Gender (male)

41 (64.1%)

Median age (years)

60 (36–85)

M protein type

IgG

28 (43.7%)

IgA

18 (28.1%)

LC

13 (20.3%)

IgD

5 (7.9%)

Hemoglobin (g/L)

97.5 (42–182)

M protein in SPE (g/L)*

35.6 (0–99.8)

24-h urine LC (mg)**

8252 (275–56,000)

BM myeloma cells (%)

26% (0–88%)

LDH > 250 U/L

12 (18.7%)

Serum β2-MG (mg/L)

6.08 (0.6–67.4)

ISS staging

I

9 (14.1%)

II

20 (31.3%)

III

35 (54.7%)

D–S staging

IA

4 (6.3%)

IB

2 (3.1%)

IIA

6 (9.4%)

IIIA

38 (59.4%)

IIIB

14 (21.9%)

CA by FISH

1q21+ 

24 (37.5%)

RB1−

28 (43.8)

DS319−

28 (43.8%)

17p−

11 (17.2%)

t (14;16)

3 (4.9%)

t (4;14)

7 (10.9%)

t (11;14)

8 (12.5%)

High risk disease

30 (46.9%)

  1. LC, light chain; SPE, serum protein electrophoresis; BM, bone marrow; LDH, lactic dehydrogenase; β2-MG, β2-microglobulin; ISS, International Staging System; D–S, Durie–Salmon; CA, cytogenetic abnormalities; FISH, fluorescence in situ hybridization; *, IgG and IgA only; **, light chain only.
Back to article page